← All trials
NCT05567016
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2023
- Primary completion
- May 31, 2025
- Completion date
- Mar 31, 2027
- First posted
- Oct 5, 2022
- Last posted
- Oct 5, 2022
- Enrollment
- 600
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Ifakara Health InstituteCollaborator
- Ifakara Health InstituteOverall official - principal investigator
- Stanford UniversityCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of BaselCollaborator
- Chan Zuckerberg InitiativeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.